Dr. Daniel A. Ermann, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 104
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
UT license 11731045-1205 -
Hematology & Oncology Physician
UT license 11731045-1205 -
Internal Medicine Physician
NE license TEP8102
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 104
- Services billed
- 1,329
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 317 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 75 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 57 | 11 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 56 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Salt Lake City, UT | 87 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Salt Lake City, UT | 33 |
| Omeprazole Other prescribers in Salt Lake City, UT | 29 |
| Allopurinol Other prescribers in Salt Lake City, UT | 25 |
| Prochlorperazine Maleate Other prescribers in Salt Lake City, UT | 25 |
| Prednisone Other prescribers in Salt Lake City, UT | 25 |
| Brukinsa (zanubrutinib) | 23 |
| Levofloxacin Other prescribers in Salt Lake City, UT | 22 |
| Ondansetron Hcl Other prescribers in Salt Lake City, UT | 21 |
| Venclexta (venetoclax) | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 50 payments worth $52,032 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $33,027 |
|---|---|
| Beone Medicines USA, Inc. | $12,654 |
| Incyte Corporation | $5,775 |
| Adc Therapeutics America, Inc. | $232 |
| Genmab U.S., Inc. | $127 |
| Pfizer Inc. | $108 |
| F. Hoffmann-la Roche AG | $75.00 |
| Novartis Pharmaceuticals Corporation | $34.72 |
| Compensation for services other than consulting (speaking, faculty) | $28,985 |
|---|---|
| Consulting Fee | $18,190 |
| Travel and Lodging | $3,172 |
| Food and Beverage | $1,685 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Jun 12, 2025 | Consulting Fee BRUKINSA · Oncology | $8,000 |
| AstraZeneca Pharmaceuticals LP May 12, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| AstraZeneca Pharmaceuticals LP Oct 16, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Oct 4, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| Beone Medicines USA, Inc. Apr 5, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Incyte Corporation Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| Incyte Corporation Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
All 30 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| Incyte Corporation Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Incyte Corporation Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV | $113 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV | $40.00 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| AstraZeneca Pharmaceuticals LP Oct 16, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Oct 4, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Sep 27, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $567 |
| AstraZeneca Pharmaceuticals LP Sep 27, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $343 |
| Incyte Corporation Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $825 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,375 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Consulting Fee BRUKINSA · Oncology | $8,000 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $757 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $476 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ · in-kind | $343 |
| Beone Medicines USA, Inc. Jun 12, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Hopewell, NJ | $80.00 |
| Incyte Corporation May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $275 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV | $137 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV | $60.00 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV | $58.83 |
| AstraZeneca Pharmaceuticals LP May 12, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Apr 30, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $197 |
| AstraZeneca Pharmaceuticals LP Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| Beone Medicines USA, Inc. Apr 5, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $1,554,506 in research payments for these studies, mostly to the institutions running them.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie Inc. · Active, not recruiting · NCT05618028 - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.